Key Highlights

  • LeMaitre Vascular shares closed down 25% at $79.
  • Q2 FY2026 net sales grew 10% to $70.4 million.
  • EPS climbed 23% to $0.74, with gross margin reaching 72.1%.
  • The company issued full-year 2026 guidance of $274.3-$278.3 million in revenue and EPS of $2.84-$2.94.

LeMaitre Vascular (NASDAQ: LMAT) shares closed down 25% at $79 despite the company reporting Q2 FY2026 net sales growth of 10% to $70.4 million, with EPS climbing 23% to $0.74.

What Happened

Gross margin reached 72.1%, behind a 34% increase in Artegraft sales, and the company provided full-year 2026 guidance, projecting revenue between $274.3 million and $278.3 million alongside EPS of $2.84 to $2.94.

Market Reaction

Shares fell sharply despite the reported sales and EPS growth, a decline that stands in contrast to the generally constructive underlying results, including the strong Artegraft sales growth and margin expansion.

Outlook

The disclosed information does not specify a reason for the decline; investors are likely to watch for further detail on whether the full-year 2026 guidance range fell short of prior market expectations.

Why did LeMaitre Vascular shares fall 25% despite growth in sales and EPS?

The disclosed information does not specify a reason for the decline beyond the reported results and guidance.

What drove LeMaitre Vascular's gross margin performance?

A 34% increase in Artegraft sales supported gross margin of 72.1%.

What is LeMaitre Vascular's full-year 2026 guidance?

Revenue of $274.3 million to $278.3 million and EPS of $2.84 to $2.94.